Modernizing infrastructures, record drug approvals, and harmonization were all positive regulatory advancements in July 2026.

David S. Thompson, CSAP, is Chief Alliance Officer at Eli Lilly and Company.

Houston’s Generation Park was selected for a $2.3B, 600,000-square-foot campus expected to add ~500 skilled jobs and expand beyond its initial configuration as demand grows. A modular, reconfigurable ...

EMA introduced its New Fee Regulation in January 2025, but what impact will the new fees and charges have on medicine developers? On 1 Jan. 2025, the European Medicines Agency (EMA) introduced a new ...

OSTP's July 2026 report to Trump diagnoses U.S. science slowdown and pushes deregulation, new funding models, reshoring, and AI-driven "Genesis Mission." Much of the report is broad science policy: ...

Indication targets anti–PD-1–refractory unresectable stage IIIB–IV melanoma, including BRAF-naïve/pretreated and adjuvant-relapsed populations, using ...

Atul Mohindra is vice president of R&D for Lonza Integrated Biologics where he brings more than 20 years of experience in cell biology, bioprocessing, media development, and process scale up ...

AI tools have arrived, but organizational readiness, data governance, and regulatory gaps now limit real-world impact. Six months after industry experts laid out their predictions for 2026, many of ...

This week’s content included Moderna's mRNA flu approval, CMO governance tips, OSTP’s deregulation push, a $2 billion oncology license, and July's regulatory wrap-up. In the first week of August, ...

Nitrosamines arise via nitrosating agents (nitrites, NO2/NOx, nitrous acids/oxides) reacting with secondary/tertiary amines or some amides, yielding high-risk N-nitroso compounds. Regulatory actions ...

Pressure-rated retention agitation can preserve batch uniformity through storage/unloading, mitigating settling and phase separation under elevated temperature and pressure common to reactive ...